title: Hemostatic agents: which is better?
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Daban
authors.forename: Guillaume
authors.initials: G
authors.lastname: de Saint Maurice
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Blot
authors.forename: Sylvain
authors.initials: S
authors.lastname: Ausset
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D015942:Factor VIIa / Q000627:therapeutic use*; D005602:France; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008887:Military Medicine / Q000379:methods*; D008889:Military Personnel; D011994:Recombinant Proteins / Q000627:therapeutic use; D012771:Shock, Hemorrhagic / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D014148:Tranexamic Acid / Q000627:therapeutic use; D014481:United States; D014947:Wounds and Injuries / Q000209:etiology / Q000401:mortality / Q000628:therapy*
chemical_list: D000933:Antifibrinolytic Agents; D006490:Hemostatics; D011994:Recombinant Proteins; D014148:Tranexamic Acid; C103587:recombinant FVIIa; D015942:Factor VIIa